Robin Dubin, Founder and Executive Director at AliveAndKickn, shared on LinkedIn:
“I think about my boys. That’s where my mind goes when a story like this one lands and this AP piece has been everywhere this week.
Hereditary cancer rarely gets national attention, so I’ll take it.
What strikes me isn’t any single trial. It’s the shape of the pipeline.
When I started this work, the conversation with a newly diagnosed family was almost entirely about surveillance. Colonoscopy every year. Scopes, scans, decisions about surgery. That was the toolkit, and we were grateful to have it.
Today there are three vaccine candidates in or entering trials aimed at intercepting Lynch-related cancer before a tumor ever forms. There’s work on early detection, on risk stratification by gene, on understanding why some carriers develop cancer and others don’t.
None of it changes what your gastroenterologist should be telling you this year. All of it could change what we ask of our children.
That’s the part I sit with. Not whether any one of these works, but that there is real science underway aimed at a future where this means something different than it means now. That’s what I want our community to hear.
Lynch syndrome affects about 1 in 279 people, and most of them don’t know it. If cancer runs young in your family, that’s a conversation worth having.”
Testing is underway on vaccines to intercept brewing colon cancer before it takes root
Other articles about Lynch syndrome on OncoDaily.